Response to Horse ATG (Thymogam, Bharat Serums and Vaccine, India) and Cyclosporine in Aplastic Anemia: A Single Centre, Retrospective Study of 60 Patients from Southern India
AbstractImmunosuppressive therapy (IST), consisting of anti thymocyte globulin and cyclosporine, is the standard of care for elderly patients and in younger patients without matched donor for stem cell transplant. In this retrospective study of 60 patients, most had non severe AA (51.6%) followed by very severe AA (26.7%) and severe AA (21.7%). The response rate at 6 months was 68.3% (complete response-3.3% and partial response-65%). Of the 45 who completed 12 months follow up, RR was 54.7% (CR-7.5%, PR-47.2 %). Eight patients died during the study period. Also, Indian data on IST is briefly reviewed.
CONCLUSION: Duration of AA, ANC and decreased ALC rate after IST might predict the response to IST, among which the rate of decreased ALC after IST is the most important predictive factor. PMID: 31793407 [PubMed - in process]
AbstractObjectiveTo investigate the potential efficacy of panaxadiol saponins component (PDS-C) in the treatment of aplastic anemia (AA) model mice.MethodsTotally 70 mice were divided into 7 groups as follows: normal, model, low-, medium-, high-dose PDS-C (20, 40, 80 mg/kg, namely L-, M-, H-PDS-C), cyclosporine (40 mg/kg), and andriol (25 mg/kg) groups, respectively. An immune-mediated AA mouse model was established in BALB/c mice by exposing to 5.0 Gy total body irradiation at 1.0 Gy/min, and injecting with lymphocytes from DBA mice. On day 4 after establishment of AA model, all drugs were intragastrically administered da...
The objective of the current study was to elucidate differences between the molecular mechanisms underlying FA and AA as well as to identify biomarkers and pathways associated with FA via bioinformatics analyses. Proteomic data were obtained from bone marrow samples of patients with FA and AA. Gene ontology analysis was performed using a Database for Annotation, Visualization and Integrated Discovery. KEGG pathway enrichment analyses were conducted using the ClueGO plug-in in Cytoscape. A DEP-associated protein-protein interaction (PPI) network was constructed using STRING and visualized in Cytoscape. A total of 114 DEPs, ...
ConclusionWe suggest a one ‐compartment population model with first‐order elimination to capture the pharmacokinetic profile for basiliximab for this patient population.
our R PMID: 31727769 [PubMed - as supplied by publisher]
The treatment of choice for paediatric severe aplastic anaemia (SAA) is currently a human leucocyte antigen (HLA) matched sibling donor (MSD) transplant, with 2-5 year overall survival of 82-92% [1 –4]. Historically, immunosuppressive therapy (IST) was given to those who lacked a MSD but matched unrelated donor (MUD) transplant is now considered an alternative upfront treatment if a donor can be found quickly . This change partly reflects excellent results from alternative donor transplan ts but also lack of consistent long-term remission for those treated with IST alone [5–7].
Publication date: Available online 9 November 2019Source: International Journal of PharmaceuticsAuthor(s): Cristian Vergallo, Giulia Torrieri, Riccardo Provenzani, Sini Miettinen, Karina Moslova, Markku Varjosalo, Maria Chiara Cristiano, Massimo Fresta, Christian Celia, Hélder A. Santos, Felisa Cilurzo, Luisa Di MarzioAbstractStanozolol (STZ) is a drug used to treat serious disorders like aplastic anemia and hereditary angioedema. It is also indicated as an adjunct therapy for the treatment of vascular disorders and growth failures. Encouraging results obtained using animal models demonstrated that STZ increases bon...
The evolution of Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) as a treatment modality has witnessed the cure of several haematological conditions such as leukaemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassaemia and aplastic anaemia . The many advances made in this domain, and the availability of excellent post transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease-free at five years after HSCT have a 10-year survival rate that exceeds 80% .
The evolution of allogeneic hematopoietic stem cell transplant (allo-HSCT) as a treatment modality has witnessed the cure of several hematologic conditions such as leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, thalassemia, and aplastic anemia . The many advances made in this domain and the availability of excellent post-transplant care have ensured increased longevity in recipients of allo-HSCT. It has been demonstrated in previous studies that patients who are disease free at 5 years after HSCT have a 10-year survival rate that exceeds 80% .